- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06793397
En fas 3 -studie för att bedöma CYB003 vid större depressiv störning (EMBRACE)
En effektivitet och säkerhet, fas III, multicenter, dubbelblind, randomiserad kontrollerad studie som jämför 2 aktiva doser av CyB003 och placebo hos berättigade deltagare med major depressiv störning
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Clinical Development
- Telefonnummer: 877-361-4003
- E-post: clinicaltrialsinfo@cybin.com
Studieorter
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekrytering
- Royal Prince Alfred Hospital
-
Huvudutredare:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australien, 4558
- Rekrytering
- Thompson Brain & Mind Healthcare (TBMH)
-
Huvudutredare:
- Adem Can
-
Kontakt:
- Megan Dutton
- Telefonnummer: +61 4160 40977
- E-post: mdutton@tbmh.org.au
-
Kontakt:
- Kristy Smyth
- Telefonnummer: +61 4324 41227
- E-post: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekrytering
- Ramsay Clinic
-
Huvudutredare:
- Malcolm Hopwood
-
Kontakt:
- Melanie Hurley
- Telefonnummer: 03 9279 3569
- E-post: research.arc@ramsayhealth.com.au
-
Kontakt:
- Grace Monigatti
- Telefonnummer: 03 9279 3569
- E-post: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australien, 3053
- Rekrytering
- Neurocentrix Research
-
Huvudutredare:
- David Barton
-
Kontakt:
- Mai-Anh Bui
- Telefonnummer: +61 3 9546 0009
- E-post: mai@neurocentrix.com.au
-
Kontakt:
- Gabriela Gonzalez
- Telefonnummer: +61 3 9959 8375
- E-post: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australien, 3168
- Rekrytering
- Monash University - Notting Hill
-
Kontakt:
- Olivia Lavalette
- Telefonnummer: 0426359494
- E-post: olivia.lavalette@monash.edu
-
Huvudutredare:
- Paul Liknaitzky
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35209
- Rekrytering
- UAB Psychiatry and Behavioral Neurology
-
Kontakt:
- Seher Premani
- Telefonnummer: 205-996-1198
- E-post: spremani@uab.edu
-
Huvudutredare:
- Peter Hendricks
-
Kontakt:
- Maggie Gossage
- E-post: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna, 85234
- Rekrytering
- Lighthouse Psychiatry
-
Kontakt:
- Chung Trinh
- Telefonnummer: 435-268-5800
- E-post: ctrinh@neosciclinicalresearch.com
-
Huvudutredare:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72204
- Indragen
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, Förenta staterna, 91206
- Rekrytering
- Behavioral Research Specialists, LLC
-
Huvudutredare:
- Jesse Carr
-
Kontakt:
- Laisha Uribe
- Telefonnummer: 888-255-5798
- E-post: laisha@brstrials.com
-
Imperial, California, Förenta staterna, 92251
- Indragen
- Sun Valley Research Center
-
Los Angeles, California, Förenta staterna, 90025
- Rekrytering
- CalNeuro Research Group
-
Huvudutredare:
- Alexander Bystritsky
-
Kontakt:
- Telefonnummer: 310-208-7144
- E-post: info@calneuroresearch.com
-
Los Angeles, California, Förenta staterna, 90025
- Rekrytering
- Lipov Medical Group
-
Kontakt:
- Brittany Juhlmann
- Telefonnummer: 262-352-8835
- E-post: brittany.juhlmann@stellacenter.com
-
Huvudutredare:
- Jacob Moussai
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- NRC Research Institute
-
Kontakt:
- Christian Ortiz
- Telefonnummer: 714-289-1100
- E-post: cortiz@nrcresearch.com
-
Huvudutredare:
- Daniel Chueh
-
Orange, California, Förenta staterna, 92866
- Rekrytering
- ATP Clinical Research
-
Huvudutredare:
- Gustavo Alva
-
Kontakt:
- Sarah Perkins
- Telefonnummer: 949-354-5353
- E-post: sarahp@pnsoc.com
-
San Juan Capistrano, California, Förenta staterna, 92675
- Rekrytering
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Huvudutredare:
- Neelima Kunam
-
Kontakt:
- Telefonnummer: 909-955-5865
- E-post: research@inlandpsych.com
-
Santa Monica, California, Förenta staterna, 90404
- Rekrytering
- Psychedelic Science Institute
-
Huvudutredare:
- Keith Heinzerling
-
Kontakt:
- Telefonnummer: 213-973-7512
- E-post: trialadmin@psychedelicsci.com
-
Stanford, California, Förenta staterna, 94305
- Indragen
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06511
- Rekrytering
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Huvudutredare:
- Ben Kelmendi
-
Kontakt:
- Daidre Chamberlain
- Telefonnummer: 203-693-1591
- E-post: enact@yale.edu
-
Kontakt:
- Terrence Ching
- Telefonnummer: 502-612-1127
- E-post: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32256
- Rekrytering
- CNS Healthcare
-
Kontakt:
- Telefonnummer: 904-281-5757
-
Huvudutredare:
- John Mark Joyce
-
Maitland, Florida, Förenta staterna, 32751
- Rekrytering
- Accel Research Sites - Maitland
-
Kontakt:
- Telefonnummer: 407-644-1165
-
Huvudutredare:
- Andrea Marrafino
-
Naples, Florida, Förenta staterna, 34105
- Rekrytering
- Aqualane Clinical Research
-
Huvudutredare:
- Matthew Baker
-
Kontakt:
- Rachel Novella
- Telefonnummer: 239-529-6780
- E-post: Rachel@Aqualaneresearch.com
-
Tampa, Florida, Förenta staterna, 33634
- Rekrytering
- K2 Medical Research Tampa
-
Huvudutredare:
- Kelley Wilson
-
Kontakt:
- Jessica Myers
- Telefonnummer: 352-500-5252
- E-post: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Indragen
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, Förenta staterna, 30060
- Rekrytering
- Psych Atlanta
-
Huvudutredare:
- Michael Banov
-
Kontakt:
- Telefonnummer: 770-422-2846
- E-post: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Rekrytering
- Rush University
-
Huvudutredare:
- Joshua Eloge
-
Kontakt:
- Stephanie Gutierrez
- Telefonnummer: 312-942-8995
- E-post: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, Förenta staterna, 70006
- Indragen
- Tandem Clinical Research
-
New Orleans, Louisiana, Förenta staterna, 70115
- Rekrytering
- Atlas Psychiatry
-
Kontakt:
- Milton Boresoff
- Telefonnummer: 504-899-1682
- E-post: m.boresoff@atlaspsychiatry.com
-
Huvudutredare:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21224
- Indragen
- Johns Hopkins Medicine
-
Rockville, Maryland, Förenta staterna, 20850
- Har inte rekryterat ännu
- Sunstone Medical, PC
-
Kontakt:
- Manish Agrawal, MD
- Telefonnummer: 301-750-3401
- E-post: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02116
- Rekrytering
- Adams Clinical Boston
-
Huvudutredare:
- Darin Dougherty
-
Kontakt:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-post: info@adamsclinical.com
-
Watertown, Massachusetts, Förenta staterna, 02472
- Rekrytering
- Adams Clinical Watertown
-
Huvudutredare:
- Stephanie Ellickson
-
Kontakt:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-post: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, Förenta staterna, 55347
- Rekrytering
- Institute for Integrative Therapies
-
Huvudutredare:
- Manoj Doss
-
Kontakt:
- Sena Ostwalt
- Telefonnummer: 6512808774
- E-post: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, Förenta staterna, 55427
- Har inte rekryterat ännu
- The Remedy Mental Health
-
Kontakt:
- Emmanuel Arhin
- Telefonnummer: (651) 382-9518
- E-post: emmanuel.arhin@theremedymn.com
-
Huvudutredare:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89119
- Rekrytering
- Redbird Research, LLC
-
Huvudutredare:
- Jelena Kunovac
-
Kontakt:
- Telefonnummer: 702-577-2000
- E-post: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, Förenta staterna, 08755
- Rekrytering
- Bio Behavioral Health
-
Kontakt:
- Jessica Sutton
- Telefonnummer: 732-244-2299
- E-post: jessica@bbhnj.com
-
Huvudutredare:
- Ashok Patel
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Har inte rekryterat ännu
- New York State Psychiatric Institute
-
Huvudutredare:
- Natalie Gukasyan
-
Kontakt:
- Alexandra Mackay
- Telefonnummer: 212-342-1424
- E-post: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, Förenta staterna, 10029
- Rekrytering
- Adams Clinical Harlem
-
Kontakt:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-post: info@adamsclinical.com
-
Huvudutredare:
- Wesley Gregory
-
The Bronx, New York, Förenta staterna, 10461
- Rekrytering
- Adams Clinical Bronx
-
Huvudutredare:
- Shama Farooq
-
Kontakt:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-post: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73112
- Indragen
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- Adams Clinical Philadelphia
-
Huvudutredare:
- Cassie Blanchard
-
Kontakt:
- Participant Navigators
- Telefonnummer: 267-376-0266
- E-post: info@adamsclinical.com
-
Philadelphia, Pennsylvania, Förenta staterna, 19462
- Rekrytering
- Flourish Research Philadelphia
-
Huvudutredare:
- Rachna Saralkar
-
Kontakt:
- Telefonnummer: 215-614-5606
-
-
Texas
-
Austin, Texas, Förenta staterna, 78737
- Indragen
- Austin Clinical Trial Partners
-
DeSoto, Texas, Förenta staterna, 75115
- Rekrytering
- Adams Clinical Dallas
-
Huvudutredare:
- Rajinder Shiwach
-
Kontakt:
- Participant Navigators
- Telefonnummer: 469-379-2494
- E-post: info@adamsclinical.com
-
Fort Worth, Texas, Förenta staterna, 76104
- Indragen
- North Texas Clinical Trials
-
Houston, Texas, Förenta staterna, 77046
- Rekrytering
- Brain Health Consultants and TMS Center
-
Huvudutredare:
- Lauren Marangell
-
Kontakt:
- Telefonnummer: 713-489-5000
- E-post: info@brainhealthconsultants.com
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- Flourish Research San Antonio
-
Huvudutredare:
- Parke Hedges
-
Kontakt:
- Xavier Martinez
- Telefonnummer: 237 210-949-0122
- E-post: xmartinez@flourishresearch.com
-
Kontakt:
- Andrea Gomez
- Telefonnummer: 122 210-949-0122
- E-post: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, Förenta staterna, 98201
- Har inte rekryterat ännu
- Core Clinical Research
-
Kontakt:
- Maria Golescu
- Telefonnummer: 425-443-9551
- E-post: maria.golescu@ccrtrial.com
-
Huvudutredare:
- James Knutson
-
Seattle, Washington, Förenta staterna, 98104
- Rekrytering
- Seattle Neuropsychiatric Treatment Center
-
Huvudutredare:
- Rebecca Allen
-
Kontakt:
- Telefonnummer: 5 206-467-6300
- E-post: research@seattlentc.com
-
-
-
-
-
Athens, Grekland, 12462
- Rekrytering
- Attikon University Hospital
-
Huvudutredare:
- Nikolaos Smyrnis
-
Kontakt:
- Thomas Karantinos
- Telefonnummer: +30697466610
- E-post: tkarantinos@gmail.com
-
Athens, Grekland, 11528
- Rekrytering
- Eginitio Hospital
-
Huvudutredare:
- Nikos Stefanis
-
Kontakt:
- Adam Adamopoulos
- Telefonnummer: +30 6976032181
- E-post: adam_adamopoulos@yahoo.com
-
Thessaloniki, Grekland, 56404
- Rekrytering
- Papageorgiou General Hospital
-
Huvudutredare:
- Georgios Papazisis
-
Kontakt:
- Ogla Vampertzi
- Telefonnummer: +306973852659
- E-post: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Irland, D24 WK80
- Rekrytering
- Sheaf House - Tallaght Adult Mental Health Service
-
Huvudutredare:
- John Kelly
-
Kontakt:
- Ann Connolly
- Telefonnummer: +353 8616 79619
- E-post: aconnolly@crp.healthcare
-
Galway, Irland, H91 VE03
- Rekrytering
- La Nua Day Hospital Mental Health Centre
-
Kontakt:
- Prathyusha Nedunuru
- Telefonnummer: +353 874283750
- E-post: pnedunuru@crp.healthcare
-
Huvudutredare:
- Shane McInerney
-
-
-
-
-
Bialystok, Polen, 15-272
- Indragen
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Polen, 85-133
- Rekrytering
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Kontakt:
- Franciszek Lauchut
- Telefonnummer: +48 790 219 501
- E-post: f.lachut@pro-mente.pl
-
Huvudutredare:
- Katarzyna Lachut
-
Gdansk, Polen, 80-546
- Rekrytering
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Kontakt:
- Monika Drzewiecka
- Telefonnummer: +48 508-348-938
- E-post: m.drzewiecka@pihouse.pl
-
Huvudutredare:
- Hanna Badzio-Jagiello
-
Gdansk, Polen, 80-214
- Har inte rekryterat ännu
- UCK
-
Huvudutredare:
- Wieslaw Jerzy Cubala
-
Kontakt:
- Natalia Sudol
- Telefonnummer: +48 669 439 740
- E-post: nat.sudol13@gmail.com
-
Warsaw, Polen, 02-957
- Har inte rekryterat ännu
- Department of Pharmacology and Physiology of CNS
-
Huvudutredare:
- Justyna Holka-Pokorska
-
Warsaw, Polen, 02-172
- Rekrytering
- MTZ Clinical Research Powered by Pratia
-
Huvudutredare:
- Monika Gawlowicz
-
-
-
-
-
Cambridge, Storbritannien, CB1 2EU
- Rekrytering
- Cambridge University Hospital NHS
-
Huvudutredare:
- Liliana Galindo
-
Kontakt:
- Tracy Assari
- Telefonnummer: +44 1223 219751
- E-post: t.assari@nhs.net
-
Kontakt:
- Emma Tudor
- Telefonnummer: +44 1223 219751
- E-post: Emma.tudor@cpft.nhs
-
Doncaster, Storbritannien, DN4 8QN
- Rekrytering
- Clerkenwell Health - Doncaster
-
Huvudutredare:
- Paul Morrison
-
Kontakt:
- Celia Creaghan
- Telefonnummer: +44 7849 640886
- E-post: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Storbritannien, EH16 4TJ
- Har inte rekryterat ännu
- NHS Research Scotland
-
Huvudutredare:
- Donald MacIntyre
-
Kontakt:
- Carrie Wardhaugh
- Telefonnummer: +44 1315375867
- E-post: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Storbritannien, G51 4TF
- Har inte rekryterat ännu
- Queen Elizabeth University Hospital
-
Huvudutredare:
- Maytal Wolfe
-
Kontakt:
- Rebecca Baird
- E-post: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Storbritannien, L7 8XP
- Har inte rekryterat ännu
- Royal Liverpool Hospital
-
Kontakt:
- Rachel Crick
- Telefonnummer: +44730 861 3597
- E-post: Rachel.Crick@merseycare.nhs.uk
-
Huvudutredare:
- Fabian Devlin
-
London, Storbritannien, EC2Y 8EA
- Rekrytering
- St Pancras Clinical Research
-
Huvudutredare:
- Martin Johnson
-
Kontakt:
- Participant Engagement Team
- Telefonnummer: +44 20 38651142
- E-post: studyinformation@stpancrasclinical.com
-
London, Storbritannien, W1U 6RP
- Rekrytering
- Clerkenwell Health - Baker Street
-
Huvudutredare:
- Alishah Suleman
-
Kontakt:
- Takunda Gwenhure
- Telefonnummer: +44 2038974867
- E-post: tgwenhure@clerkenwellhealth.com
-
Kontakt:
- Victor Jardim
- Telefonnummer: +44 2038974867
- E-post: vjardim@clerkenwellhealth.com
-
London, Storbritannien, W1G9 RU
- Rekrytering
- Re:Cognition Health
-
Huvudutredare:
- Dimitrios Paschos
-
Kontakt:
- Telefonnummer: +44-0800-802-1030
-
London, Storbritannien, SE5 9RS
- Rekrytering
- King's College London
-
Kontakt:
- Catheine Bird
- E-post: catherine.bird@kcl.ac.uk
-
Kontakt:
- Paige Seath
- E-post: paige.seath@kcl.ac.uk
-
Huvudutredare:
- James Rucker
-
London, Storbritannien, W1G 8DR
- Indragen
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Storbritannien, NE4 5PL
- Rekrytering
- Edwardson Building - Campus for Ageing and Vitality
-
Kontakt:
- Victoria Wilson
- Telefonnummer: +44 191 246 8647
- E-post: victoria.wilson3@cntw.nhs.uk
-
Kontakt:
- Rebecca Woodhouse
- E-post: Rebecca.Woodhouse@cntw.nhs.uk
-
Huvudutredare:
- Mourad Wahba
-
Reading, Storbritannien, RG7 8PA
- Rekrytering
- Ascend Clinical Research
-
Huvudutredare:
- Pamela Walters
-
Kontakt:
- Alexandra Diaz
- Telefonnummer: +44 118 3045905
- E-post: adiaz@ascendclinical-research.com
-
Sheffield, Storbritannien, S4 7QQ
- Rekrytering
- Sheffield Health and Social Care NHS Foundation Trust
-
Huvudutredare:
- William Gann
-
Kontakt:
- Mishell Cunningham
- Telefonnummer: +44 114 271 6731
- E-post: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
-
Prague, Tjeckien
- Har inte rekryterat ännu
- Institute of neuropsychiatric Care (INEP)
-
Huvudutredare:
- Alexander Nawka
-
Kontakt:
- Telefonnummer: +420 222 201 020
- E-post: info@inep.cz
-
Prague, Tjeckien
- Har inte rekryterat ännu
- Psyon s.r.o.
-
Huvudutredare:
- Tomas Palenicek
-
Kontakt:
- Telefonnummer: +420 774 401 161
- E-post: info@psyon.cz
-
Předměstí, Tjeckien
- Har inte rekryterat ännu
- A-SHINE s.r.o.
-
Huvudutredare:
- Lubos Janu
-
Kontakt:
- Blanka Vopelková
- Telefonnummer: +490 777 732 244
- E-post: blanka.vopelkova@seznam.cz
-
-
-
-
-
Berlin, Tyskland, 10117
- Har inte rekryterat ännu
- Charité Universitaetsmedizin Berlin
-
Huvudutredare:
- Michael Koslowski
-
Kontakt:
- Telefonnummer: +49 30 450 617734
- E-post: psychedelika-studien@charite.de
-
Frankfurt am Main, Tyskland, 60528
- Har inte rekryterat ännu
- University Hospital Frankfurt
-
Huvudutredare:
- Andreas Reif
-
Kontakt:
- Tanja Scharf
- Telefonnummer: +49 69 6301 86078
- E-post: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Tyskland, 68159
- Har inte rekryterat ännu
- Central Institute of Mental Health
-
Kontakt:
- Karin Bopp
- Telefonnummer: 3016 +49 621 1703 3163
- E-post: Karin.bopp@zi-mannheim.de
-
Huvudutredare:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Tyskland, 66421
- Har inte rekryterat ännu
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Huvudutredare:
- Matthias Riemenschneider
-
Kontakt:
- Christine Geiger
- Telefonnummer: +49 6841 1624227
- E-post: christine.geiger@uks.eu
-
Kontakt:
- Aline Freer
- Telefonnummer: +49 6841 1614219
- E-post: aline.freer@uks.eu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Experimentell: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Placebo-jämförare: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Tidsram: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Tidsram: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Tidsram: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Tidsram: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Tidsram: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: Felix Mazer, Cybin IRL Limited
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CYB003-003
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .